Kikuo Yasui News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes Using iPS Cells from I Peace, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine

Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes Using iPS Cells from I Peace, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Palo altoUnited statesKikuo yasuiHeartseed incI peace incBusiness wireChief operating officer

Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes Using iPS Cells from I Peace,

TOKYO & PALO ALTO, Calif. (BUSINESS WIRE) #Heartseed Heartseed Inc. ("Heartseed"), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure and I Peace Inc. ("I Peace"), a leading GMP cell CDMO in Palo Alto, California, have collaborated to generate cardiomyocytes using multipl.

Palo altoUnited statesKikuo yasuiHeartseed incI peace incChief operating officer

Heartseed Announces the Presentation of HS-001, an Investigational Stem Cell-Derived Therapy for the Treatment of Advanced Heart Failure at the 71st Annual Meeting of the Japanese College of Cardiology

TOKYO (BUSINESS WIRE) Sep 11, 2023

Kikuo yasuiYuki ichiharaHeartseed incTokyo women medical universityMeeting of the japanese college cardiologyDepartment of cardiovascular surgeryAnnual meetingJapanese collegeCardiovascular surgeryTokyo womenMedical universityBusiness wire

Heartseed Inc : Heartseed raises 2 billion JPY in series D funding to accelerate development of iPSC-derived stem cell therapy for heart failure

Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), today announced it has raised 2 billion JPY at Series D round, bringing

Kikuo yasuiKeiichi fukudaGewinn nurIi limited partnershipHeartseed incPequity coNovo nordiskJapan coIv limited partnershipSumitomo mitsui trust investmentKeio innovation initiativeInnovation fundJapan co investArcus south east asiaAtsushi sakanoAspex management

As the world grays, Japan s aging market showcases high-tech senior care

May 10, 2021 Six years ago, Atsushi Nakanishi launched Triple W with nothing but the seed of an idea and an overwhelming passion to realize it. Today, the startup is the creator and seller of DFree the world’s first wearable device for urinary incontinence. The tiny, noninvasive device uses ultrasound to monitor the volume of urine in the user’s bladder in real time. When the bladder reaches its threshold, DFree sends an alert to the user’s smartphone to tell them it is time to go to the bathroom. Nakanishi credits the ground-breaking product to a eureka moment in 2013. Due to uncontrollable diarrhea, he soiled himself in the street and, not long after, he learned that sales in Japan of adult diapers had surpassed that of baby diapers. Seeing both the need and demand for a product that lets people know when to use the bathroom, he “felt inspired” despite having zero medical background.

Wojciech bulaKikuo yasuiNaoto shimazuYoshinori abeKeiichi fukudaKenji suzukiKota kuboTomohiro tadaAtsushi nakanishiDaniel maggsHeartseed incTai medical serviceAi medical service incWorld health organizationZubie incJapan service award